Population effect of ART therapy to Reduce HIV Transmission - PopART A study to assess the feasibility of increased HIV voluntary counselling and testing.

Slides:



Advertisements
Similar presentations
Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July Ties Boerma HIV Department Surveillance,
Advertisements

TB/HIV Research Priorities: TB Preventive Therapy.
Assessing integrated SRH and HIV services in Kenya, Swaziland and Malawi: Evidence on efficiency and cost Timothy Abuya on Behalf of the Integra Team.
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
NATIONAL INSTITUTES OF HEALTH: National Institute of Allergy and Infectious Diseases National Institute of Mental Health National Institute on Drug Abuse.
The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Attaining Realistic and Substantial Reductions in HIV Incidence: Model Projections of Combining Microbicide and Male Circumcision interventions in Rural.
Know Your epidemic: The value of population-based household surveys Eva Kiwango Senior Strategic Information Advisor United Nations Joint Programme on.
Supporting community action on AIDS in developing countries Liza Tong Programme Manager International HIV/AIDS Alliance “Whose Value Counts”: A community.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.
A generation of children free from AIDS is not impossible Children and AIDS Fourth Stocktaking Report, 2009.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
Voluntary Counseling and Testing (VCT) for HIV
Treatment as prevention: a new paradigm for HIV control? Richard Hayes.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,
PMTCT at Different Levels of Care: The Uganda Experience Dr. Saul Onyango National PMTCT Coordinator Ministry of Health 1 1.
Involving the Community in HIV/AIDS Treatment Support Programmes: An Evidence-Based Approach.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
Comprehensive HIV Prevention Strategies for Most at Risk Populations (MARPs) Anne Goldzier Thomas, Ph.D. US Department of Defense/PEPFAR Ethiopia National.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
What do models estimate to be the impacts on HIV incidence of various percentages of people with HIV on ART ? National AIDS Trust Treatment as Prevention.
HIV Treatment and Care Research priorities Facilitator – Dr Saphonn Vonthanak 12 participants 29 agreed topics –not grouped on methodology or subject category.
AIDS IN ASIA – PRIORITIZING AND SUSTAINING THE RESPONSE IN THE ECONOMIC CRISIS Hanoi September 2009 ADB Consultant Ross McLeod.
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
Integrated Health Programs for Women and Children: Lessons from the Field Dr. Ambrose Misore Project Director, APHIA II Western, PATH’s Kenya Country Program.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
‘ There is an increasing recognition that public health often provides and added and compelling justification for safeguarding human rights, despite the.
Progress to date and Plans for Year 5 Overcoming HIV/AIDS epidemic in Ukraine Programme supported by the Global Fund 11 th Stakeholders’ meeting 22 nd.
Psychosocial support model for community - based ART initiatives: Zimbabwe experience. Sostain Moyo G.Kadzirange, L. S. Zijenah, T. Kufa. L. Gwanzura,
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
Exploring the potential impact of ART in reducing HIV transmission. Geoff Garnett, Jeff Eaton, Tim Hallett & Ide Cremin Imperial College London.
Communities and research : the necessity for dialogue Bruno Spire President of AIDES Researcher at INSERM.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
IAS Policy and Advocacy priority on Treatment as Prevention Carlos F. Cáceres Multidisciplinary Research on ARV-based Prevention 30 June 2013 Kuala Lumpur.
Female Condom: A Powerful Tool for Protection. Global Consultation on the Female Condom Review evidence for STI and pregnancy prevention Share program.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
Regional Videoconference Addressing Stigma and Discrimination of HIV/AIDS in Africa Thursday, April 2, 2009 UNAIDS Perspective Susan Timberlake, Senior.
ARV-Based Prevention: Perspective from Epidemiology & Modelling Tim Hallett Imperial College London.
Thorny Issues in HIV Vaccine Trials Saul Walker Policy Advisor IAVI.
Maximising the use of VCT data for programs' planning and evaluation; experience from developing longitudinal studies of FSWs in Bali LUH PUTU LILA WULANDARI.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
Getting more value for money: working with countries and partners toward greater effectiveness and efficiency Peter Stegman, Senior Economist.
The HIV Care Continuum: A Tool for Driving Systematic Change to Support Better Engagement in Care Jeffrey S. Crowley Distinguished Scholar/ Program Director.
De Beers Response to HIV/AIDS 19 th June 2006 World Bank Group- CommDev Workshop.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
The impact of HIV/AIDS on Botswana (The effects of the pandemic in our country.)
Main achievements and further developments 2006 and beyond: Overcoming HIV/AIDS epidemic in Ukraine (programme (programme supported by the Global Fund)
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
33 MEETING OF THE UNAIDS PROGRAMME COORDINATING BOARD GENEVA, SWITZERLAND DECEMBER 2013 THE EQUITY DEFICIT: UNEQUAL AND UNFAIR ACCESS TO HIV TREATMENT,
Zindoga Mukandavire Social and Mathematical Epidemiology Group London School of Hygiene and Tropical Medicine, UK Improving health worldwide
STATE OF THE EPIDEMIC AND THE RESPONSE PROMISES, PROGRESS AND PROBLEMS DR. ALEX COUTINHO MD MPH Executive Director Infectious Diseases Institute.
Prevention of Mother-to-Child Transmission of HIV: Scale-up of Critical Services in Uganda (District- based Approach) Edward Bitarakwate, MD, MPH Technical.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
Outline The Global Fund Strategy emphasizes the Key Populations
Peter D Ghys*, Mary Mahy*, Jeff Eaton**, Samir Bhatt**,
HPTN 071 (PopART): Have we reached the targets after two years of the PopART intervention IAS Paris July 2017 Richard Hayes.
IAS Abstract TUAC0406LB Increasing knowledge of HIV status among men: a cluster-randomised trial of community-based distribution of oral HIV self-test.
HPTN Modelling Centre symposium “Recent advances in mathematical modelling to inform HIV prevention research activities and directions” IAS 2017 in.
Zimbabwe’s shift towards treat all: national country context
Richard hayes London school of hygiene & Tropical Medicine
Katharina Hauck On behalf of the HPTN 071 Study Team
Dr. Velephi Okello, Principal Investigator, MaxART Trial
National Department of Health: South Africa
HIV/AIDS Prevention Through Schools
HIV/AIDS Prevention Through Schools
Petchsri Sirinirund Advisor to HIV/AIDS Policy and Programme
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

Population effect of ART therapy to Reduce HIV Transmission - PopART A study to assess the feasibility of increased HIV voluntary counselling and testing (VCT) and universal access to antiretroviral therapy (ART) to reduce HIV incidence Dr Ade Fakoya, Senior Advisor: HIV and Health Services, International HIV/AIDS Alliance

PopART Membership United Kingdom Imperial College London – Geoffrey Garnett – Sarah Fidler – Christophe Fraser – Becky Baggaley – Jonathan Weber Institute of Global Health – Peter Piot LSHTM – Richard Hayes – David Ross – Debby Watson-Jones – Johanna Hanefeld MRC CTU – Adbel Babiker – Sheena McCormack UCL – Andrew Phillips International HIV/ AIDS Alliance – Ade Fakoya Africa: PIs Uganda ( MRC-UVRI) Zambia ( Zambart)

The Prevention- Treatment gap….. By the end 2007: 3 million were receiving ART --about 1 million people added 6.7 million in need 2.7 million new infections

PopART – The Goal A comprehensive feasibility study to address the key assumptions underpinning the Universal Testing and Treatment concept (UTT) To determine whether a larger randomised trial is possible

‘Know your status’. ‘Take Lifelong treatment if you are positive’ ‘Grace’ 18 years old Both brother and mother are positive HIV positive ( 12 years ) CD4 – 61 Viral Load 110,000 Not on ARV treatment

PopART- four levels of exploration ‘Logistical feasibility’ – pilot studies in districts in Uganda and Zambia. ‘ Test the approach’ ‘acceptability’ – individual, community, population, government ‘wider implications’ – health economics human rights, drug issue ( resistance, toxicity, ) Mathematical modelling ( data to support assumptions,

Feasibility Study Design Engage with country stakeholders National stakeholder and community engagement and acceptability of interventions Compilation of data on HIV epidemiology, testing and treatment monitoring Development of HIV incidence measurement Field testing of novel point of care assays

Some key questions Key area Main issues Acceptance of Treatment as prevention At individual, community and country levels, What will be the uptake of ARV treatment for those who may not need it for clinical need Logistical Provision of treatment in health systems which are already over- stretched Is it logistically feasible, what coverage is actually possible, will it divert funding from other areas, will it increase waiting lists for those who need treatment to actually stay alive Starting and staying on treatmentDrop out rate, the survival, the residual HIV transmission Resistance to ARV drugsWhat is the optimum regimen for TAP, what will the strategy do to population levels of resistance at what level resistance will assumptions become how will resistance be monitored at a population level

Some key questions Key area Main issues Marginalised groupsIn a generalised epidemic, what will be the focus and special attention required for hard to reach groups including sex workers, men who have sex with men, drug users, people who move (including migrants ) Human rightsWill a focus on a public health approach further erode human rights, is it acceptable for individuals to take treatment when they don’t need it. What about other health needs? What about marginalised populations? AdherenceWhat level of adherence is important to ensure success?

PopART: Feasibility Mathematical modelling Undertake critical evaluation of current models Develop an HIV transmission model Inform the design of the Cluster randomised trial( CRT), Determine the predicted effect size; For a given effect size, the model will be used to estimate the minimum proportion of the HIV+ve population that will need to be identified and treated. Estimate the minimum threshold that needs to be reached to ensure a substantial public health impact.

PopART Modelling Led by IC What % HIV+ threshold of detection is required to demonstrate an effect What % uptake of ART is required to demonstrate an effect What is the risk of viral drug resistance and toxicity What is the cost benefit analysis ► Set parameters for RCT

Epidemiology led by LSHTM, MRC CTU two selected communities of approximately people comprehensive VCT package ( house-to-house testing, mobile testing units, work place testing and village facilities. All individuals identified as HIV+ve will be immediately referred into local standard care health care facilities Random selected population (10% of the total) enrolled into a pilot RCT: either standard care (CD4 driven initiation of ART) or a UTT strategy where irrespective of CD4 T-cell count ART will be immediately offered.

PopART Pilot - Human Rights Human rights based approaches an explicit part of the feasibility and pilot study. Two broad elements: 1/to better understand the effect and interaction of PopART interventions on human rights, 2/develop best practice human rights approaches especially in community interventions but at all levels of rights based approaches for treatment as prevention.

PopART Pilot - Human Rights Specific objectives To explore the human right dimensions of the concept of treatment as prevention (TAP) and ensure that the pilot study adheres to human rights principles, including the right to information, participation, non-discrimination and equity. To explore areas of investigation relating to the acceptability and feasibility of treatment as prevention at individual, community and national level To understand the potential barriers to universal HIV testing and immediate uptake of HIV treatment. To develop individual and community based interventions that address the barriers to successful recruitment and participation in any future CRT of treatment as prevention, while ensuring human rights of the individual are fulfilled, protected and guaranteed.

PopART Pilot - Human Rights How will this work in practice? Human rights/social science working group consisting of staff from each of the implementing partners, including the MRC Uganda and Zambart who develop and implement a detailed methodology. Local Community advisory group in each country *Ethics reference/advisory group made up of key external experts/individuals who can advise on the human rights dimension of treatment as prevention and the issues which arise during the execution of the study.

PopART Pilot - Human Rights Possible Methods include* Ethnographies In-depth interviews over time (3 year study) Work with policymakers at national level and district level. The human rights part of the research will focus on the individual level, but also on how to achieve greater acceptability for the inclusion of rights based approaches with policymakers at all levels. * The HR working group will develop these in detail as part of the study and will be led by country context.

PopART Pilot - Human Rights Your thoughts? Specifically around the areas of study and investigation More detail and information – Ade Fakoya at the AIDS Alliance – Johanna Hanefeld at London School of Hygiene and Tropical Medicine

Combination prevention- no magic bullets

Summary I There will be a population effect of ARV treatment roll out Despite the enormous assumptions in the mathematical modelling, UTT and Universal Access to HIV treatment care and prevention are closer together than it would appear Need community engagement to find out what affected communities and individuals think.